Skip to main content
. 2022 Nov 1;241:109678. doi: 10.1016/j.drugalcdep.2022.109678

Fig. 2.

Fig. 2

Unadjusted plots of the percents and counts of patients who received buprenorphine, methadone, or naltrexone by cohort and over time.